AIM ImmunoTech expands Ampligen Long COVID patent protection across Europe, UK through 2041

Reuters2026/09/02 12:43

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AIM ImmunoTech expanded Ampligen patent protection in Europe and the UK for treating Long COVID, with coverage expected through June 2041.
Protection covers three forms of patent rights, with the European opposition window closing Aug. 25, 2026 with no challenge filed.
Claims cover therapeutic dsRNA use, including dosing regimens and intranasal, intravenous, or inhalation delivery methods.
Disclosure follows a newly issued U.S. patent covering Ampligen combined with pembrolizumab for cancer treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020843PRIMZONEFULLFEED9819651) on September 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AIM ImmunoTech expands Ampligen Long COVID patent protection across Europe, UK through 2041

You may also like

Crypto prices